Net profit doubled: Multibagger pharma stock hits fresh 52-week high!
The stock has experienced significant buying activity, yielding multibagger returns of more than 110 per cent in the last one year.
Today, the shares of Piramal Pharma Limited rallied 2.69 per cent. Additionally, the stock hits fresh 52-week high mark of Rs 166.60 apiece on BSE. Furthermore, the scrip witnessed a spurt in volume by more than 4.40 times. The company's current market capitalization standing at Rs 20,419.70 crore.
Stock performance:
On Monday, the stock opened at Rs 157.25, with the previous closing being Rs 150.30. The 52-week high and low are Rs 166.60 and Rs 69.91, respectively as per BSE.
Recent Development - Q4FY24 Highlights:
- Revenue from Operations saw a significant increase of 18 per cent YoY, reaching Rs 2,552 crore, driven by robust growth in the CDMO and ICH businesses.
- EBITDA surged by 48 per cent YoY to Rs 556 crore in Q4FY24 and by 61 per cent YoY for FY24, primarily fueled by revenue growth, operating leverage, cost optimization, and operational excellence initiatives.
- In Q4FY24, the Profit After Tax (PAT) saw a significant surge, totaling Rs 132 crore. This marks a substantial increase, more than doubling the figure recorded in Q4FY23, which stood at Rs 50 crore.
DSIJ's DSIJ's ‘Mid Bridge’ service recommends well researched Mid-Cap stocks for smart investing. If this interests you, do download the service details here.
About the Company:
Piramal Pharma Limited (PPL) provides a diverse range of products and services through comprehensive manufacturing capabilities across various global facilities and a wide-reaching distribution network spanning hundreds of countries. This encompasses Piramal Pharma Solutions (PPS), which serves as an integrated Contract Development and Manufacturing Organisation (CDMO), Piramal Critical Care (PCC), specializing in Complex Hospital Generics, and the India Consumer Healthcare business catering to over-the-counter products.
Business Development:
Piramal Pharma Limited's revenue is primarily generated from three key segments: Contract Development and Manufacturing Organizations (CDMO), Complex Hospital Generics, and Consumer Health.
In terms of product-wise breakdown, CDMO contributes approximately 57.8 per cent, Complex Hospital Generics account for around 29.36 per cent, and Consumer Health contributes roughly 12.84 per cent to the total revenue.
Geographically, the revenue is distributed across various regions. North America leads with approximately 45 per cent, followed by India and Europe, each contributing around 20 per cent. Japan accounts for about 4 per cent of the revenue, while the remaining regions collectively contribute 11 per cent.
Furthermore, the stock has experienced significant buying activity, yielding multibagger returns of more than 110 per cent in the last one year.
Disclaimer: The article is for informational purposes only and not investment advice.